Current and future treatments of secondary osteoporosis

Best Pract Res Clin Endocrinol Metab. 2014 Dec;28(6):885-94. doi: 10.1016/j.beem.2014.09.004. Epub 2014 Sep 16.

Abstract

Osteoporosis is commonly associated with menopause and ageing. It can, however, also be caused by diseases, lifestyle, genetic diseases, drug therapies and other therapeutic interventions. In cases of secondary osteoporosis, a common rule is the management of the underlying condition. Healthy habits and calcium and vitamin D supplementation are also generally advised. In cases of high risk of fracture, specific antiosteoporosis medications should be prescribed. For most conditions, the available evidence is limited. Special attention should be paid to possible contraindications of drugs used for the treatment of postmenopausal or senile osteoporosis. Bisphosphonates are the most widely used drugs in secondary osteoporosis, and denosumab or teriparatide have been also assessed in some cases. Important research is needed to develop more tailored strategies, specific to the peculiarities of the different types of secondary osteoporosis.

Keywords: osteoporosis; secondary osteoporosis; treatment.

Publication types

  • Review

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Bone Density Conservation Agents / therapeutic use*
  • Denosumab
  • Diphosphonates / therapeutic use*
  • Humans
  • Osteoporosis / chemically induced
  • Osteoporosis / drug therapy*
  • Osteoporosis / etiology*
  • Teriparatide / therapeutic use*

Substances

  • Antibodies, Monoclonal, Humanized
  • Bone Density Conservation Agents
  • Diphosphonates
  • Teriparatide
  • Denosumab